Oncology Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Oncology Market: By Drug Class (Antimetabolites, Antineoplastics, XPO1 Inhibitor, Mitotic Inhibitors, Biomarker testing, Multikinase Inhibitors), By Disease Indications (Lung cancer, Breast cancer, Prostate cancer, Cervical cancer, Colorectal cancer, Acute Myeloid Leukemia, Others), By Treatment Options (Surgery, Chemotherapy, Radiation therapy, Bone marrow transplant, Immunotherapy, Hormone therapy, Targeted drug therapy, Cryoablation, Radiofrequency ablation), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Oncology Market Introduction
2.1. Global Oncology Market – Taxonomy
2.2. Global Oncology Market –Definitions
2.2.1. By Drug Class
2.2.2. By Disease Indications
2.2.3. By Treatment Options
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Oncology Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Oncology Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4.Global Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Oncology Market Forecast, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Antimetabolites
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. MAbs
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XPO1 Inhibitor
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Mitotic Inhibitors
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Multikinase Inhibitors
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antineoplastics
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6.Global Oncology Market Forecast, By Disease Indications, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Lung cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Breast cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Prostate cancer
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Cervical cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Colorectal cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Acute Myeloid Leukemia
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. Market Opportunity Analysis Global Oncology Market Forecast, By Treatment Options, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Surgery
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Chemotherapy
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Immunotherapy
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Targeted Therapy
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Bone marrow transplant
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Bone marrow transplant
7.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Hormone therapy
7.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Cryoablation
7.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
7.9. Cryoablation
7.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.9.3. Market Opportunity Analysis
7.10. Radiofrequency ablation
7.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.10.3. Market Opportunity Analysis
7.11. Radiation Therapy
7.11.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.11.1.3. Market Opportunity Analysis
7.12. Others
7.12.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.12.3. Market Opportunity Analysis
8. Market Opportunity Analysis Global Oncology Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Hospital Pharmacy
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacy
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacy
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Oncology Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel, and Region, 2022 – 2028
10.  North America Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Antimetabolites
10.1.2. Antineoplastics
10.1.3. XPO1 Inhibitor
10.1.4. Mitotic Inhibitors
10.1.5. Biomarker testing
10.1.6. Multikinase Inhibitors
10.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Lung cancer
10.2.2. Breast cancer
10.2.3. Prostate cancer
10.2.4. Cervical cancer
10.2.5. Colorectal cancer
10.2.6. Acute Myeloid Leukemia
10.2.7. Others
10.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Surgery
10.3.2. Chemotherapy
10.3.3. Radiation therapy
10.3.4. Bone marrow transplant
10.3.5. Immunotherapy
10.3.6. Hormone therapy
10.3.7. Targeted drug therapy
10.3.8. Cryoablation
10.3.9. Radiofrequency ablation
10.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
10.7. North America Oncology Market Dynamics – Trends
11.  Europe Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Antimetabolites
11.1.2. Antineoplastics
11.1.3. XPO1 Inhibitor
11.1.4. Mitotic Inhibitors
11.1.5. Biomarker testing
11.1.6. Multikinase Inhibitors
11.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Lung cancer
11.2.2. Breast cancer
11.2.3. Prostate cancer
11.2.4. Cervical cancer
11.2.5. Colorectal cancer
11.2.6. Acute Myeloid Leukemia
11.2.7. Others
11.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Surgery
11.3.2. Chemotherapy
11.3.3. Radiation therapy
11.3.4. Bone marrow transplant
11.3.5. Immunotherapy
11.3.6. Hormone therapy
11.3.7. Targeted drug therapy
11.3.8. Cryoablation
11.3.9. Radiofrequency ablation
11.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Oncology Market – Opportunity Analysis Index, By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
11.7. Europe Oncology Market Dynamics – Trends
12.  Asia-Pacific Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Antimetabolites
12.1.2. Antineoplastics
12.1.3. XPO1 Inhibitor
12.1.4. Mitotic Inhibitors
12.1.5. Biomarker testing
12.1.6. Multikinase Inhibitors
12.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Lung cancer
12.2.2. Breast cancer
12.2.3. Prostate cancer
12.2.4. Cervical cancer
12.2.5. Colorectal cancer
12.2.6. Acute Myeloid Leukemia
12.2.7. Others
12.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Surgery
12.3.2. Chemotherapy
12.3.3. Radiation therapy
12.3.4. Bone marrow transplant
12.3.5. Immunotherapy
12.3.6. Hormone therapy
12.3.7. Targeted drug therapy
12.3.8. Cryoablation
12.3.9. Radiofrequency ablation
12.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Rest of Asia-Pacific
12.6. Asia-Pacific Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
12.7. Asia-Pacific Oncology Market Dynamics – Trends
13.  Latin America Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Antimetabolites
13.1.2. Antineoplastics
13.1.3. XPO1 Inhibitor
13.1.4. Mitotic Inhibitors
13.1.5. Biomarker testing
13.1.6. Multikinase Inhibitors
13.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Lung cancer
13.2.2. Breast cancer
13.2.3. Prostate cancer
13.2.4. Cervical cancer
13.2.5. Colorectal cancer
13.2.6. Acute Myeloid Leukemia
13.2.7. Others
13.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Surgery
13.3.2. Chemotherapy
13.3.3. Radiation therapy
13.3.4. Bone marrow transplant
13.3.5. Immunotherapy
13.3.6. Hormone therapy
13.3.7. Targeted drug therapy
13.3.8. Cryoablation
13.3.9. Radiofrequency ablation
13.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Argentina
13.5.3. Rest of Latin America
13.6. Latin America Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
13.7. Latin America Oncology Market Dynamics – Trends
14.  Middle East and Africa Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
14.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.1.1. Antimetabolites
14.1.2. Antineoplastics
14.1.3. XPO1 Inhibitor
14.1.4. Mitotic Inhibitors
14.1.5. Biomarker testing
14.1.6. Multikinase Inhibitors
14.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Lung cancer
14.2.2. Breast cancer
14.2.3. Prostate cancer
14.2.4. Cervical cancer
14.2.5. Colorectal cancer
14.2.6. Acute Myeloid Leukemia
14.2.7. Others
14.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Surgery
14.3.2. Chemotherapy
14.3.3. Radiation therapy
14.3.4. Bone marrow transplant
14.3.5. Immunotherapy
14.3.6. Hormone therapy
14.3.7. Targeted drug therapy
14.3.8. Cryoablation
14.3.9. Radiofrequency ablation
14.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Saudi Arabia
14.5.2. GCC Countries
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2022 – 2028
14.7. MEA Oncology Market Dynamics – Trends
15.  Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, By Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. ABBVIE INC.AMGEN, INC.
15.2.2. ASTELLAS PHARMA INC.
15.2.3. ASTRAZENECA PLC
15.2.4. BRISTOL-MYERS SQUIBB COMPANY
15.2.5. F. HOFFMANN-LA ROCHE AG
15.2.6. JOHNSON & JOHNSON
15.2.7. MERCK & CO., INC.
15.2.8. NOVARTIS INTERNATIONAL AG
15.2.9. PFIZER, INC.
15.2.10. Celgene Corporation (U.S.)
16.  Research Methodology
17.  Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

  • ABBVIE INC.AMGEN, INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BRISTOL-MYERS SQUIBB COMPANY
  • JOHNSON & JOHNSON
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC.
  • Celgene Corporation (U.S.)
  • HOFFMANN-LA ROCHE AG

Description

1. Executive Summary
2. Global Oncology Market Introduction
2.1. Global Oncology Market – Taxonomy
2.2. Global Oncology Market –Definitions
2.2.1. By Drug Class
2.2.2. By Disease Indications
2.2.3. By Treatment Options
2.2.4. By Distribution Channel
2.2.5. By Region
3. Global Oncology Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Oncology Market Dynamic Factors – Impact Analysis
3.6. Impact of COVID 19 on The Market
3.7. Three Forecast Scenarios – Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players’ Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4.Global Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Oncology Market Forecast, By Drug Class, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1. Antimetabolites
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. MAbs
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XPO1 Inhibitor
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Mitotic Inhibitors
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Multikinase Inhibitors
5.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Antineoplastics
5.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6.Global Oncology Market Forecast, By Disease Indications, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1. Lung cancer
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Breast cancer
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Prostate cancer
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Cervical cancer
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Colorectal cancer
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Acute Myeloid Leukemia
6.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Others
6.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
7. Market Opportunity Analysis Global Oncology Market Forecast, By Treatment Options, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1. Surgery
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Chemotherapy
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Immunotherapy
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Targeted Therapy
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Bone marrow transplant
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Bone marrow transplant
7.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.6.3. Market Opportunity Analysis
7.7. Hormone therapy
7.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.7.3. Market Opportunity Analysis
7.8. Cryoablation
7.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.8.3. Market Opportunity Analysis
7.9. Cryoablation
7.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.9.3. Market Opportunity Analysis
7.10. Radiofrequency ablation
7.10.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.10.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.10.3. Market Opportunity Analysis
7.11. Radiation Therapy
7.11.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.11.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.11.1.3. Market Opportunity Analysis
7.12. Others
7.12.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
7.12.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.12.3. Market Opportunity Analysis
8. Market Opportunity Analysis Global Oncology Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1. Hospital Pharmacy
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacy
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacy
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. Global Oncology Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1. North America
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel, and Region, 2022 – 2028
10.  North America Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
10.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.1.1. Antimetabolites
10.1.2. Antineoplastics
10.1.3. XPO1 Inhibitor
10.1.4. Mitotic Inhibitors
10.1.5. Biomarker testing
10.1.6. Multikinase Inhibitors
10.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Lung cancer
10.2.2. Breast cancer
10.2.3. Prostate cancer
10.2.4. Cervical cancer
10.2.5. Colorectal cancer
10.2.6. Acute Myeloid Leukemia
10.2.7. Others
10.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Surgery
10.3.2. Chemotherapy
10.3.3. Radiation therapy
10.3.4. Bone marrow transplant
10.3.5. Immunotherapy
10.3.6. Hormone therapy
10.3.7. Targeted drug therapy
10.3.8. Cryoablation
10.3.9. Radiofrequency ablation
10.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.5.1. U.S.
10.5.2. Canada
10.6. North America Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
10.7. North America Oncology Market Dynamics – Trends
11.  Europe Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
11.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.1.1. Antimetabolites
11.1.2. Antineoplastics
11.1.3. XPO1 Inhibitor
11.1.4. Mitotic Inhibitors
11.1.5. Biomarker testing
11.1.6. Multikinase Inhibitors
11.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Lung cancer
11.2.2. Breast cancer
11.2.3. Prostate cancer
11.2.4. Cervical cancer
11.2.5. Colorectal cancer
11.2.6. Acute Myeloid Leukemia
11.2.7. Others
11.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Surgery
11.3.2. Chemotherapy
11.3.3. Radiation therapy
11.3.4. Bone marrow transplant
11.3.5. Immunotherapy
11.3.6. Hormone therapy
11.3.7. Targeted drug therapy
11.3.8. Cryoablation
11.3.9. Radiofrequency ablation
11.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.5.1. Germany
11.5.2. UK
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Oncology Market – Opportunity Analysis Index, By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
11.7. Europe Oncology Market Dynamics – Trends
12.  Asia-Pacific Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
12.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.1.1. Antimetabolites
12.1.2. Antineoplastics
12.1.3. XPO1 Inhibitor
12.1.4. Mitotic Inhibitors
12.1.5. Biomarker testing
12.1.6. Multikinase Inhibitors
12.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Lung cancer
12.2.2. Breast cancer
12.2.3. Prostate cancer
12.2.4. Cervical cancer
12.2.5. Colorectal cancer
12.2.6. Acute Myeloid Leukemia
12.2.7. Others
12.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Surgery
12.3.2. Chemotherapy
12.3.3. Radiation therapy
12.3.4. Bone marrow transplant
12.3.5. Immunotherapy
12.3.6. Hormone therapy
12.3.7. Targeted drug therapy
12.3.8. Cryoablation
12.3.9. Radiofrequency ablation
12.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. ASEAN
12.5.5. Rest of Asia-Pacific
12.6. Asia-Pacific Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
12.7. Asia-Pacific Oncology Market Dynamics – Trends
13.  Latin America Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
13.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.1.1. Antimetabolites
13.1.2. Antineoplastics
13.1.3. XPO1 Inhibitor
13.1.4. Mitotic Inhibitors
13.1.5. Biomarker testing
13.1.6. Multikinase Inhibitors
13.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Lung cancer
13.2.2. Breast cancer
13.2.3. Prostate cancer
13.2.4. Cervical cancer
13.2.5. Colorectal cancer
13.2.6. Acute Myeloid Leukemia
13.2.7. Others
13.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Surgery
13.3.2. Chemotherapy
13.3.3. Radiation therapy
13.3.4. Bone marrow transplant
13.3.5. Immunotherapy
13.3.6. Hormone therapy
13.3.7. Targeted drug therapy
13.3.8. Cryoablation
13.3.9. Radiofrequency ablation
13.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
13.5.1. Brazil
13.5.2. Argentina
13.5.3. Rest of Latin America
13.6. Latin America Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel  and Country, 2022 – 2028
13.7. Latin America Oncology Market Dynamics – Trends
14.  Middle East and Africa Oncology Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Million)
14.1. By Drug Class Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.1.1. Antimetabolites
14.1.2. Antineoplastics
14.1.3. XPO1 Inhibitor
14.1.4. Mitotic Inhibitors
14.1.5. Biomarker testing
14.1.6. Multikinase Inhibitors
14.2. By Disease Indications Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Lung cancer
14.2.2. Breast cancer
14.2.3. Prostate cancer
14.2.4. Cervical cancer
14.2.5. Colorectal cancer
14.2.6. Acute Myeloid Leukemia
14.2.7. Others
14.3. By Treatment Options Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Surgery
14.3.2. Chemotherapy
14.3.3. Radiation therapy
14.3.4. Bone marrow transplant
14.3.5. Immunotherapy
14.3.6. Hormone therapy
14.3.7. Targeted drug therapy
14.3.8. Cryoablation
14.3.9. Radiofrequency ablation
14.4. By Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Hospital Pharmacy
14.4.2. Retail Pharmacy
14.4.3. Online Pharmacy
14.5. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
14.5.1. Saudi Arabia
14.5.2. GCC Countries
14.5.3. South Africa
14.5.4. Rest of MEA
14.6. MEA Oncology Market – Opportunity Analysis Index, By By Drug Class, By Disease Indications, By Treatment Options, By Distribution Channel and Country, 2022 – 2028
14.7. MEA Oncology Market Dynamics – Trends
15.  Competition Landscape 
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, By Drug Class Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. ABBVIE INC.AMGEN, INC.
15.2.2. ASTELLAS PHARMA INC.
15.2.3. ASTRAZENECA PLC
15.2.4. BRISTOL-MYERS SQUIBB COMPANY
15.2.5. F. HOFFMANN-LA ROCHE AG
15.2.6. JOHNSON & JOHNSON
15.2.7. MERCK & CO., INC.
15.2.8. NOVARTIS INTERNATIONAL AG
15.2.9. PFIZER, INC.
15.2.10. Celgene Corporation (U.S.)
16.  Research Methodology
17.  Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX